Diosynth Biotechnology is all about the cGMP and protein. The company is a leading provider of cGMP (Current Good Manufacturing Practices) production for recombinant therapeutic proteins and peptides. Diosynth's line of proteins include monoclonal antibodies, cancer vaccines, fusion proteins, hormones, cancer vaccines, and anti-coagulants. The company also offers contract manufacturing, process development, and validation services. Diosynth has manufacturing facilities in the US, serving a wide range of customers. The company (which originally began operating in 1923) was a subsidiary of Akzo Nobel until Schering-Plough bought that company's pharmaceutical operations in 2007.

QLT Inc. company was founded in 1981 and is headquartered in Vancouver, Canada. QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, as well as OT-730, a prodrug of a beta adrenergic antagonist (a type of beta blocker) under investigation for the treatment of glaucoma.

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications and vitamin drops. The Health Care segment is engaged in the manufacture and sale of general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. The Company has 49 subsidiaries and 15 associated companies.

Prolexys Pharmaceuticals wouldn't necessarily characterize proteins as difficult to characterize, especially not if it's using the technology it developed. The biotech research firm's HySpec and HyNet are high-throughput systems for protein expression, purification, and analysis. Prolexys, formerly known as Myriad Proteomics, has also developed its own bioinformatics to put together protein interaction maps from the data generated by HySpec and HyNet. The company has been focusing on cancer research, working with groups such as Columbia University and the Tower Cancer Research Foundation to study advanced solid tumors. Myriad Genetics spun off Prolexys, which was founded in 2001, as a private company in 2003.

InterMune, Inc. company was founded in 1998 and is headquartered in Brisbane, California. InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The company has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes CAPACITY, a Phase III program evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF; and a research program focusing on pirfenidone analog ITMN-520. The hepatology portfolio comprises the HCV protease inhibitor compound ITMN-191, which is in Phase Ib, a second-generation HCV protease inhibitor research program; and a research program evaluating a new target in hepatology. It has license and collaboration agreements with Maxygen Holdings Ltd.; Array BioPharma, Inc.; Boehringer Ingelheim International GmbH; Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.; Novartis Corporation; Connetics Corporation; Eli Lilly & Company; Genentech, Inc.; ALZA Corporation; Amgen Inc; and Marnac, Inc. and its co-licensor, /KDL GmbH.

The health care products subsidiary of Bayer AG, Bayer HealthCare develops and manufactures products for humans and animals. Bayer HealthCare operates through four divisions: Pharmaceuticals (represented by Bayer Schering Pharma and Bayer Healthcare Pharmaceuticals); Consumer Care (OTC medications); Animal Health (veterinary drugs); and Medical Care (diagnostic equipment makers including Diabetes Care and MEDRAD). Bayer HealthCare's better-known products include YAZ birth control pills, antibiotic Avelox, erectile dysfunction treatment Levitra, Bayer Aspirin, Alka-Seltzer, One-A-Day vitamins, and the flea preventative Advantage.

SomaLogic helps in the hunt for proteins. Its aptamer arrays bind to proteins in such a way that multiple protein targets can be identified at once. Life sciences researchers use the company's arrays to identify proteins related to angiogenesis (the formation of new blood vessels) and inflammation. Data gathered from this work could be used to develop new drugs and diagnostics for a variety of diseases. SomaLogic has partnered with Quest Diagnostics to develop diagnostics that can measure many proteins at once. As part of the arrangement, Quest Diagnostics made a $15 million investment in the company.

BioMarin Pharmaceutical Inc. company was founded in 1996 and is headquartered in Novato, California. BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The company's approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used to treat genetic disease called mucopolysaccharidosis (MPS)VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used to treat mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase.Its clinical development products comprise various product candidates for the treatment of genetic diseases, which include PEG-PAL, an enzyme substitution therapy under Phase I clinical development to treat phenylketonurics, which are not responsive to Kuvan; 6R-BH4, a Phase II clinical development product for the treatment of multiple cardiovascular indications, including sickle cell disease; and GALNS, an enzyme replacement therapy for MPS Type IV or Morquio Syndrome Type A (MPS IV A), a lysosomal storage disease. In addition, the company is conducting preclinical development of various other enzyme product candidates for genetic and other diseases, including a small molecule for the treatment of Duchenne muscular dystrophy. Further, BioMarin holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. The company sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Europe, and internationally. It has a strategic alliance with Merck Serono S.A. and joint venture with Genzyme Corporation.

Obagi Medical Products, Inc. company was founded in 1988 and is headquartered in Long Beach, California. Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based products, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, rosacea and soft tissue deficits, such as fine lines and wrinkles. The Company markets and sells a range of systems and related products for the enhancement of skin health. Its principal product line is its Obagi Nu-Derm System. Its Obagi Nu-Derm System is a prescription-based topical skin health system that enhances the skin's overall health by correcting photo damage using drugs that, by definition, work at the cellular level, resulting in a reduction of the visible signs of aging. In January 2009, the Company launched the Obagi Rosaclear System.

Carma Laboratories, Inc. company was founded by Alfred Woelbing, who developed the formula for Carmex in 1937 as a treatment for his own cold sores. Carma Laboratories wants to make it easier for you to smile and sit. The family-owned-and-operated company is most famous for its retro yellow-lidded vials of Carmex lip balm. The company also makes Am-Ren, a zinc-oxide based diaper rash ointment, and LANEX hemorrhoid ointment to soothe cracked and painful tissues elsewhere. Once sold mostly in the Midwest and the ski areas of the Rockies, Carmex soothes lips in all 50 states, Canada, Australia, and Europe.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.